Clinical Activity of Avelumab in Thymic Epithelial Tumors
| Patient Number | WHO Histology | Treatment Dose (mg/kg) | Best Response | Number of Doses | Duration of Response (weeks) |
|---|---|---|---|---|---|
| 1 | B3 thymoma | 20 | cPR | 1 | 14 |
| 2 | B3 thymoma | 20 | SD | 3 | – |
| 3 | B2 thymoma | 20 | uPR | 1 | 17 |
| 4 | Thymic carcinoma | 10 | SD | 8 | – |
| 5 | B2 thymoma | 10 | SD | 18 | – |
| 6 | B2 thymoma | 10 | uPR | 1 | 4 |
| 7 | B3 thymoma | 10 | PD | 6 | – |
| 8 | B1 thymoma | 10 | cPR | 10 | 12 |
cPR confirmed partial response, SD stable disease, uPR unconfirmed partial response, PD progressive disease